Philadelphia/Center City 1528 Walnut Street Suite 1205 Philadelphia, PA 19102





Philadelphia/King Of Prussia 216 Mall Blvd Suite#1 King Of Prussia, PA, 19046

TYRUKO (natalizumab-sztn)

ORDER FORM Date: ____

1 1 1 () (natalizumab-sztr			CIOIUI					
	PATIENT INFO		RMATION					
Name:	Phone:			DOB:		SEX: M □	F □	
□NKDA Allergies:				Weight lbs/kg:				
PHYSICIAN INFORMATION								
,		Practice Name:						
			e Contact Name: Office Contact #:					
Phone: Fax: Email			es):					
	RE	FERRAL STAT	US					
□New Referral □Referral Renewal □Medi	cation/O	rder Change	☐Benefits Ve	erification Only	□Discor	ntinuation Or	der	
TYRUKO: is an integrin receptor antagonist indi ☐ Multiple Sclerosis (MS) TYRUKO is indicated as monotherapy for the treatment relapsing-remitting disease, and active secondary progrece ☐ Crohn's Disease (CD) TYRUKO is indicated for inducing and maintaining clinic disease with evidence of inflammation who have had are inhibitors of TNF-α. Important Limitations: In CD, TYRUKO	of relapsi essive dise ical respon i inadequa	ng forms of multipase, in adults. The search remission are response to, or	in adult patients	s with moderately to plerate, conventiona	o severely ac al CD therap	ctive Crohn's vies and		
DIAGNOSIS Please provide ICD-10 code DIAGNOSIS Please provide ICD-10 code PRE-MEDICATION Tylenol PO 650mg		PATIEN DO 300 Oth FRE Eve Oth LAS Avc Dat LAI	EQUENCY ry 4 weeks for a ser ST DOSAGE OF onex	= seron □Tysabr	i	onth		
		REQUI	REQUIRED DOCUMENTATION CHECKLIST:					
WARNINGS AND PRECAUTIONS https://www.pi.amgen.com/-/media/Project/Amgen/Repositorypi-amgen-com/Riabni/riabni_pi_english.pdf ORDERING PROVIDER		Pat Ins Re- ant Ple	ient Demograpurance Card/Ircent labs to incitigen and any case Confirm Prent Medication	ohics offormation clude CBC, CMP, other recent labs rovider is registe	JCV and F	lep B surface		
Signature X		Date		NP	1			

______ Phone ______ Fax ___